Short summary

A review of all patients treated for Small-Cell Lung Cancer with combined chemo-radiotherapy at the Department of Oncology at Vejle hospital in 2018 and 2019.

Rationale

The treatment of patients with limited disease small cell lung cancer (LD-SCLC) has not changed during the last decade and consists of 4 series of chemotherapy concomitant with thoracic radiotherapy of 45 Gray in 30 fractions twice daily. The risk of relapse is significant. In a recent study from Norway, treatment results were improved by increasing the radiation dose to 60 Gray in 40 fractions, still twice daily. To gain more knowledge of the treatment results of danish patients we will do a retrospective analysis of all patients treated for LD-SCLC with chemo-radiotherapy at Vejle Hospital during the years 2018 and 2019. This knowledge will help form a new national prospective study.

Description of the cohort

All patients (approximately 30) treated at Vejle Hospital for limited disease small cell lung cancer between 2018 and 2019.

Data and biological material

Demographic data, disease stage, tumorsite, pathology report, results of CT scans, follow-up visits and reported side effects, treatment times, later hospital admissions, later treatment, time and cause of death. Treatment plan evaluation and dose distribution

Collaborating researchers and departments

Department of Oncology, Vejle Hospital

• Charlotte Kristiansen, MD
• Rune Slot Thing, Physicist
• Mikkel Drøgemüller Lund, Physicist